Global Leaders Unite for Groundbreaking Summit
This November, London will play host to a momentous gathering of senior leaders from some of the world’s most prominent regulatory authorities, pharmaceutical companies, health technology organisations, academic institutions, and patient advocacy groups. The Medicines and Healthcare products Regulatory Agency (MHRA) and the Drug Information Association (DIA) are set to debut the first-ever DIA-MHRA Global Summit, bringing together a diverse array of experts to discuss pivotal issues in healthcare.
Participants will include representatives from notable organisations such as the US Food and Drug Administration (FDA), India’s Central Drugs Standard Control Organisation (CDSCO), Swissmedic, Australia’s Therapeutic Goods Administration (TGA), and various industry leaders like Microsoft, GSK, AstraZeneca, IQVIA, BioNTech, and many others. This collaborative effort aims to explore how enhanced global cooperation can expedite the delivery of safe, effective, and innovative healthcare solutions for patients worldwide.
Fostering Innovation Through Collaboration
Scheduled for 16 and 17 November 2026, the Summit coincides with a significant agenda of events throughout London Life Sciences Week. It promises to serve as a unique international platform for regulators, industry leaders, academics, investors, technology innovators, and representatives from patient groups. The discussions will revolve around how healthcare systems can synergise to foster innovation while ensuring public trust and patient safety remain paramount.
Under the banner of “Global Collaboration for Safer and Smarter Health Innovation”, the programme will delve into some of the most pressing opportunities and challenges faced by the healthcare sector today. Key topics will include regulatory innovation, advanced therapies, the role of artificial intelligence, health data management, patient access, rare diseases, investment in life sciences, and the dynamics of international regulatory cooperation.
Insights from Leading Experts
The Summit will feature a roster of influential voices from across the life sciences landscape, reflecting the diverse expertise required to shape the future of health innovation. Among the speakers from the pharmaceutical sector are Sir Jonathan Symonds of GSK, Dr Cindy Verst from IQVIA, Dr Edward Piper of AstraZeneca, and Dr Virginia Acha from MSD. Additionally, prominent trade association representatives like Dan O’Connor (ABPI) and Chris Molloy (BIA) will lend their insights.
International regulatory leaders are also set to participate, including Professor Tony Lawler from Australia’s Therapeutic Goods Administration, Dr Sara Ibrahimi of the FDA, H.E. Dr Hisham S. Aljadhey from the Saudi Food and Drug Authority, and several other esteemed officials from regulatory bodies across the globe, including top executives from the MHRA.
Incorporating Patient Perspectives
A key feature of the discussions will be the emphasis on patient perspectives. Contributions from individuals such as Julia Vitarello of Mila’s Miracle Foundation, Professor David Fajgenbaum from Every Cure, and other patient advocates will ensure that the voices of those directly affected by healthcare decisions are heard. This inclusion highlights the importance of patient-centric approaches in healthcare innovation.
Sessions dedicated to digital transformation, in silico trials, and the utilisation of real-world data will showcase experts like Professor Michael von Forstner from MedGenie, Dr Umang Patel of Microsoft, and Professor Alastair Denniston from the University of Birmingham, among others. Their insights will shed light on how technology can be harnessed to enhance healthcare outcomes.
Exploring Investment in Life Sciences
The Summit will also examine investment and growth opportunities within the life sciences sector, featuring leading investors and policy experts. Notable figures such as Dame Kate Bingham from SV Health Investors, Chris Hollowood of Syncona Investment Management, and Lord Willetts, Chair of the Regulatory Innovation Office, will discuss the future of funding and policy in the sector.
Attendees will benefit from the opportunity to engage with a remarkable line-up of global leaders, participate in dedicated networking sessions, and gain early insights into crucial announcements from the MHRA that aim to establish the Agency’s aspirations for world-class regulatory science and innovation.
Tickets for this landmark event are currently available for purchase. Interested participants can register to attend and be part of a transformative dialogue that promises to shape the future of healthcare.